Clinical trials
AML, Adult clinical trials
Below are recruiting aml, adult clinical trials, each written for real people, not researchers. We’re tracking 65 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06420063RecruitingPhase 1/Phase 2
Two-step CAR-T therapy for AML with CD33/CD123
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
Beijing, Beijing MunicipalityAges 6–90 - NCT06022003RecruitingPhase 2
Azacitidine plus gilteritinib for FLT3-mutated AML
This trial tests whether adding an oral chemotherapy pill (azacitidine) to the targeted drug gilteritinib helps people whose FLT3-mutated AML came back or didn't respond after their first treatment. The goal is to see if the combination is more effective than gilteritinib alone.
AmiensAges 18 years+ - NCT06313437RecruitingPhase 1
Revumenib with 7+3 and midostaurin for AML
This trial tests a new drug called revumenib combined with a strong chemotherapy regimen (7+3) and midostaurin for people with newly diagnosed AML that has specific gene mutations (FLT3 and NPM1). The goal is to see if this combination works better than standard treatments.
New Haven, ConnecticutAges 18–75 - NCT06014489RecruitingPhase 2
New combination for AML in people who can't have intensive chemo
This trial tests a new combination of two drugs—venetoclax and azacitidine—for people with acute myeloid leukemia (AML) who can't have standard intensive chemo. The goal is to see if adding a boosting medicine (cobicistat) makes the treatment work better and is safe for you.
's-HertogenboschAges 18 years+ - NCT06329999Recruiting
CMGV for recurrent AML and high-risk MDS
This study tests a new treatment called CMGV for adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has returned or is not improving. It is for people who may be older or have had other blood disorders.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06307054RecruitingPhase 1
CLL-1 CAR-NK cells for relapsed or refractory AML
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05839392Recruiting
Targeting MECOM/EVI1 in AML
This trial studies new ways to target a specific genetic change in acute myeloid leukemia (AML), called MECOM or atypical 3q26 rearrangements. If your leukemia test shows one of these changes, the study may offer a treatment approach aimed at that target.
PiacenzaAges 18 years+ - NCT05947344RecruitingPhase 1
Testing STI-8591 for advanced acute myeloid leukemia
This early-stage study tests STI-8591 in people with advanced acute myeloid leukemia (AML) or certain related blood cancers. It mainly aims to find a safe dose and see whether the treatment can work for patients whose disease did not respond to standard care or who cannot get it.
Hangzhou, ZhejiangAges 18 years+ - NCT07117422Recruiting
Venetoclax and decitabine for untreated AML in older or frail adults
This study tests a combination of two oral and IV medicines (venetoclax and decitabine) for older adults or people who cannot receive strong chemotherapy for newly diagnosed acute myeloid leukemia (AML). The goal is to see if this gentler treatment can help control the disease with fewer side effects.
HebeiAges 65 years+ - NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Birmingham, AlabamaAges 18 years+ - NCT06533761RecruitingPhase 1
Eganelisib alone or with chemo for relapsed AML
This trial tests an experimental drug called eganelisib, either alone or with the chemotherapy drug cytarabine, for people with relapsed or refractory acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It aims to see if the drug is safe and can help control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07587944Recruiting
Blood Markers to Predict AML Treatment Response
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
Fuzhou, FujianAges 18 years+ - NCT07591649RecruitingPhase 1/Phase 2
NK cells for high-risk blood cancers before transplant
This study tests a new type of immune cell therapy (called AdaptNK cells) for patients with high-risk myeloid diseases (blood cancers affecting bone marrow cells) who are preparing for a stem cell transplant. The goal is to help control the cancer and prepare your body for the transplant.
Minneapolis, MinnesotaAges 18 years+ - NCT07328191Recruiting
Transfusion guided by quality of life for MDS or AML
This study is for people with MDS or AML who are not receiving treatment to cure the disease and need regular blood transfusions. It looks at whether using a quality-of-life questionnaire can guide transfusion decisions, to see if fewer transfusions can keep you feeling well.
NiceAges 18 years+ - NCT05909501Recruiting
Study of geriatric checkups for new AML treatment plans
This study looks at whether geriatric (age-related health) evaluations help doctors choose better treatment for newly diagnosed AML (a type of leukemia). It may help translate older adults’ needs into a clearer, safer treatment plan.
Philadelphia, PennsylvaniaAges 50 years+ - NCT06066905Recruiting
Study of chidamide and azacitidine for AML patients with MRD after transplant
This trial tests whether a combination of two drugs, chidamide and azacitidine (AZA), can help people with acute myeloid leukemia (AML) who still have small amounts of leukemia cells (called MRD) after a stem cell transplant. The goal is to see if this treatment can clear those leftover cells and lower the chance of the leukemia coming back.
Guangzhou, GuangdongAges 18 years+ - NCT07131059Recruiting
Study for MRD-positive AML in remission
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT06649227RecruitingPhase 1
CD19 CAR-T cells for hard-to-treat AML
This study tests a new type of immunotherapy (CAR-T cells that target CD19) for adults with acute myeloid leukemia (AML) that has not responded to treatment or has come back. It aims to see if these CAR-T cells are safe and can help control the leukemia.
LilleAges 18 years+ - NCT06513273Recruiting
New treatments for AML in the real world
This study looks at how well new AML medicines work in everyday medical practice, outside of clinical trials. If you are starting a newer AML drug like gilteritinib, an IDH inhibitor, oral azacytidine, or others, you may be able to join.
San Giovanni RotondoAges 18 years+ - NCT07163728Recruiting
Leptin as a marker for chemo sensitivity in new AML
This study is looking at a substance called leptin in the blood of people with newly diagnosed acute myeloid leukemia (AML). The goal is to see if leptin levels can help doctors predict how well chemotherapy will work, which could guide better treatment choices.
Fuzhou, FujianAges 18 years+ - NCT05305859RecruitingPhase 2
Venetoclax, chidamide, and azacitidine for hard-to-treat AML
This Phase 2 trial tests whether adding three medicines—venetoclax, chidamide, and azacitidine—can help adults whose AML has come back or did not respond to treatment. It may help shrink or control the leukemia and improve outcomes for people who fit the study’s health and lab requirements.
Xiamen, FujianAges 18 years+ - NCT05025098RecruitingPhase 2
Targeted treatment versus standard care for older blood cancer patients
This Phase 2 trial compares a “precision” treatment plan with standard therapy for older adults with AML or MDS. It aims to improve outcomes while using treatments that may be better suited for people who cannot have intensive chemotherapy.
LørenskogAges 60 years+ - NCT06891144Recruiting
Study of older adults with AML getting intensive treatment
This study follows people aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who are receiving strong chemotherapy. It aims to learn more about their health outcomes and better understand the disease in this age group.
AngersAges 60 years+ - NCT05603884RecruitingPhase 2
New treatment plan for older adults with newly diagnosed AML
This trial studies a two-part chemotherapy plan for older adults newly diagnosed with acute myeloid leukemia (AML) who can’t take the usual standard induction treatment. It aims to improve how well treatment works while taking into account age and other health conditions.
Xiamen, FujianAges 60 years+
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
AML, Adult trials by city
Studies with a site in or near these metro areas.
AML, Adult trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for aml, adult?
- Yes. Clin2 currently lists 65 recruiting aml, adult studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a aml, adult trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a aml, adult trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.